Live workshop walk-through of Mexico's notificación sanitaria pathway for cosmetics and personal-care products. Format requirements, label compliance, and the cost-and-timeline reality of going to market through Sephora MX, Amazon MX, and modern trade.
Mexico is the second-largest beauty market in Latin America and the fastest-growing for premium and masstige imports. This 60-minute workshop, hosted by our Mexico City office, walks you through every step a global brand needs to take to land cleanly under COFEPRIS — from product classification to first invoice.
You will leave with a printable checklist, a benchmark cost-and-timeline grid, and a recording of the full Q&A.
Recording shared with all registrants 24h after the live session
One-click registration — calendar invites land in your inbox the moment you sign up.
Register nowPractical, no-fluff takeaways you can act on the same week.
COFEPRIS classification rules and which Class I–III pathway applies to your device
How to structure a sanitary registration via a COFEPRIS-listed legal representative
Realities of port clearance and SAT customs documentation for medical and pharma imports
Lifecycle obligations — pharmacovigilance, technovigilance, renewals
Tight, well-rehearsed, and always ends on time.
Introductions, attendee map, audio check.
Snapshot of growth drivers, recent regulatory shifts, and what changed in the past 12 months.
Live walk-through of the documents, dossiers, and decision points an entering brand will face.
Vigilance, renewals, port clearance, recall procedures, change-control.
Open-floor questions answered by the speaker.
How to book a 1:1 follow-up consultation and access the slide deck.
Mario heads Taevas' Latin-America practice from Mexico City. He is a COFEPRIS-listed legal representative and has filed sanitary registrations across Mexico, Colombia, Chile and Peru for medical devices, pharmaceuticals and consumer-health brands.
Connect on LinkedInA São Paulo-led briefing on what it actually takes to launch and price a pharmaceutical product in Brazil today — ANVISA dossier expectations, CMED pricing pathways, post-launch SUS dynamics, and the most common rejection reasons in 2026.
How a competent Indian Authorized Representative shortens a 14-month entry into 4–5. Channel strategy, Nykaa/Amazon onboarding, BIS compliance, ladder pricing, and Instagram-led D2C builds — all condensed into one hour.
A focused 45-minute briefing on the 2026 EU MDR amendments — extended Article 120 transitional periods, the digital UDI pilot, and how Authorised Representative obligations have shifted. Aimed at non-EU brands holding (or seeking) CE marking.
